1. Pink Sheet

BeiGene’s Tevimbra And The End Of The COVID Inspection Era

 
• By Bridget Silverman

US FDA approves the PD-1 inhibitor 20 months after user fee goal, resolving one of the last applications delayed by China’s extended pandemic travel restrictions.

Conveyor-with-glass-ampoules
• Source: Shutterstock

The US FDA’s approval of BeiGene, Ltd.’s PD-1 inhibitor Tevimbra (tislelizumab-jsgr) removes one of the last novel agent applications delayed by COVID-19 from the agency’s review queue.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers